Regulatory Risks Will Hinder Ophthalmology Trials Yet Future Upside Emerges
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
07 Aug 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$14.00
9.9% undervalued intrinsic discount16 Aug
US$12.62
1Y
44.6%7D
0.5%